Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY4UMW)

Drug Name
Atovaquone Drug Info
Synonyms
Acuvel; Atavaquone; Mepron; Pron; Wellvone; Atovaquone GlaxoSmithKline brand; Glaxo Wellcome brand of atovaquone; GlaxoSmithKline brand of atovaquone; Malarone Pediatric; BW 566C; BW 566C80; Hydroxynaphthoquinone 566C80; Atovaquone & Interleukin 12; BW 556C-80; BW 566C-80; BW-A 566C; DRG-0084; Hydroxynaphthoquinone, 566C80; Mepron (TN); Mepron (antipneumocystic); ATO & IL-12; Atovaquone (USP/INN); Atovaquone [USAN:BAN:INN]; CRL-8131 & Atovaquone; 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxy-naphthalene-1,2-dione; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; 566C80 hydroxynaphthoquinone; 566C80, hydroxynaphthoquinone; ATQ
Indication
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Approved [1]
Therapeutic Class
Antifungal Agents
Cross-matching ID
PubChem CID
74989
ChEBI ID
CHEMBL575568
CAS Number
CAS 94015-53-9
TTD Drug ID
DMY4UMW
INTEDE Drug ID
DR0158
ACDINA Drug ID
D00849

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Artemisinin DMOY7W3 Malaria 1F40-1F45 Approved [1]
Leflunomide DMR8ONJ Arthritis FA20 Approved [4]
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [5]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [6]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [7]
B-Octylglucoside DMMO75G Discovery agent N.A. Investigative [7]
Orotate DMMB29S Discovery agent N.A. Investigative [8]
Lauryl Dimethylamine-N-Oxide DM3W2OE Discovery agent N.A. Investigative [7]
1,4-Naphthoquinone DMTCMH7 Discovery agent N.A. Investigative [6]
Dihydroorotate DM76BGZ Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [10]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [11]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [12]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [13]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [14]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [15]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [16]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [17]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [11]
Verapamil DMA7PEW Angina pectoris BA40 Approved [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) TT3PQ2Y PYRD_PLAF7 Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [3]

References

1 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
2 Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
3 Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol. 2002 Apr;58(1):19-27.
4 Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
5 Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
6 Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
7 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8 Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
9 Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16.
10 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.